# Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma

> **NCT06023875** · PHASE2 · UNKNOWN · sponsor: **Xuekui Liu** · enrollment: 30 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Locally Advanced Operable

## Interventions

- **DRUG:** Cadonilimab
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06023875
- **Lead sponsor:** Xuekui Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-19
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06023875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06023875, "Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06023875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*